TEMPE, Ariz., May 7, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nutraceutical company, Health Enhancement Products, Inc. (HEPI) today announced the appointment of John S. Neubauer as its new President and Chief Operating Officer. Neubauer will be responsible for the implementation of corporate strategies and development of operations and staff.
Howard Baer, Chief Executive Officer of Health Enhancement Products, Inc., stated, "We are pleased that we were able to attract an industry veteran like John S. Neubauer, given his wealth of leadership experience and a proven track record in building nutraceutical companies. John will be instrumental in helping us to address the challenges and changes presented by the U.S. healthcare marketplace. We believe that he will be a tremendous asset to our organization and we welcome him to our team."
John S. Neubauer brings to Health Enhancement Products, Inc. more than 20 years experience in the healthcare and marketing industries. While with Herbalife International he was Director of Domestic and Worldwide Operations. With Cell Tech, Inc. (a major distributor of Blue Green Algae), he was Chief Operating Officer. He was also Senior VP of Starlight International and VP of International Marketing for Uni-Vite, Inc. From 1981 to 1987 Mr. Neubauer held several top positions with Deloitte & Touche Tohmatsu International, including that of Director of Corporate Finance. Mr. Neubauer holds a B.A. degree from Ripon College and a MBA degree from the Graziadio School of Business at Pepperdine University and a diploma from University of Madrid, Madrid, Spain.
John S. Neubauer, President and Chief Operating Officer commented, "We believe that ProAlgaZyme has the potential to be the dietary supplement that could alter our approach to personal health management. It could redirect the dietary supplement industry's reliance on multiple vitamin and herbal products, making it the secondary choice for health and wellness. ProAlgaZyme appears to improve the wellness of those who have medical issues and concerns and enhance the health of all others. The market for this product is just now being entered with promising results from medical practitioners and consumers. As the new President and COO of Health Enhancement Products Inc., I joined the company because I want to participate in the reshaping of the dietary supplement market that I believe ProAlgaZyme is well positioned to lead."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (HEPI) is a nutraceutical company directed specifically at the development and marketing of supplementary health-enhancing products using only pure, all-natural and herbal extracts. In particular, Health Enhancement's products use beneficial herbal extracts, vitamins, minerals, and botanical extracts in varying combinations to address common or specific illnesses.
The Company's primary product is ProAlgaZyme, an immune system enhancer that is produced from algae grown in 100% purified water. The algae produce an enzyme as a means of protecting itself from exposure to outside disease and harmful bacteria. Recent studies undertaken by the Company have indicated that ProAlgaZyme may support the immune system. Heath Enhancements is currently doing internal trials on several illnesses and diseases with ProAlgaZyme, including various types of cancer, HIV/AIDS, diabetes and Chronic Fatigue Syndrome.
This press release may contain forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.